HIVClinicalForum
Meeting category
Date(s)
7 Jun 2022
Program Language
English
Location
Paris, France
Meeting type
Hybrid Meeting
CME credits
5
Organizer

European HIV Clinical Forum 2022

Related Enduring Materials

Enduring Materials
Session 1 | Antiretroviral Therapy 2022 - State of ART Plenary Lectures - 09:10
09:10 CEST
International and European Guidelines - Similarities and Differences
Caroline Sabin, PhD
Medical Statistics and Epidemiology, University College London (UCL), United Kingdom
09:35 CEST
Resistance Considerations in Choice of Regimen
Daniele Armenia, PhD
Saint Camillus International University of Health Sciences, Italy
10:00 CEST
Pharmacological Considerations in Choice of Regimen
Saye Khoo, MD, PhD
Royal Liverpool University Hospital; University of Liverpool, United Kingdom
10:25 CEST
Comorbidity and Toxicity Considerations in Choice of Regimen
Esteban Martínez, MD, PhD
Hospital Clínic & University of Barcelona, Spain
Session 2 | Starting and Switching Antiretroviral Therapy in 2022 - 11:30
11:30 CEST
Considerations in Switching to Newer Regimens in Patients Suppressed on Older Drugs
Gary Rubin, MD, MCFP, AAHIVS
University of Toronto, Canada
11:55 CEST
Clinical Case (Focused on Starting and Switching Therapy)
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
Session 3 | HIV Prevention in 2022 - 13:45
13:45 CEST
Update on Therapeutic Options for HIV Prevention
David Jilich, MD, Ph.D
Hospital Na Bulovce, Czech Republic
14:10 CEST
How to Choose Between Oral and IM PrEP for Each Individual
Jean-Michel Molina, MD, PhD
Saint-Louis/Lariboisière Hospitals and University of Paris, France
14:35 CEST
Clinical Case (Focused on Prevention)
Emma Rubenstein, MD, MPH
Hôpital Saint-Louis, France
Session 4 | Optimal Care of Highly Treatment Experienced Patients - Now and in the Future - 15:30
15:30 CEST
Current and Evolving Therapeutic Options for Highly Treatment Experienced Patients
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
15:55 CEST
Integrating Multiple Novel Agents for Optimal Care of Multiclass Resistant Patients
Anna Maria Geretti, MD, PhD, FRCPath
University of Rome, Italy / King's College London, United Kingdom
16:10 CEST
Clinical Case (Focused on Highly Treatment Experienced Patients)
Josep Llibre, MD, PhD
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
Language